The FDA granted orphan drug status to Rafael Pharmaceuticals' CPI-613, or devimistat, which is being developed as a treatment for patients ages 60 and older with relapsed/refractory acute myeloid leukemia. The company's ongoing late-stage study of the candidate in combination with chemotherapy is expected to be finished in October 2022.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.